文献速递妇产科病理细胞病理与分子病理

人群背景下子宫内膜癌分子检测的启动:实践考量与陷阱

Initiation of molecular testing of endometrial carcinomas in a population-based setting: practical considerations and pitfalls.
PubMed 文献 · Histopathology · 2024-11-28

该研究报道了北爱尔兰自2023年3月1日起对活检诊断的子宫内膜癌集中进行分子分型的经验。

要点

  • 活检即可完成TCGA分子分型,结果可在手术前获得并整合入最终报告。
  • 262例中NSMP占45%、MMRd占24%、p53abn占23.7%、POLEmut占7.3%。
  • 6.5%为多重分类器,其中MMRd-p53abn最多(9例)。

核心结论

  • 在未选择人群中开展子宫内膜癌活检分子检测可行,可指导管理并整合入切除标本报告。

研究设计与样本

  • 人群为基础的研究,北爱尔兰4个病理实验室自2023年3月1日起将活检诊断的子宫内膜癌转至中央分子病理实验室。
  • 采用定制NGS panel检测POLE和TP53全编码区及MSI,并行ER、p53、MMR免疫组化。

主要发现

  • TCGA分组:POLEmut 19例(7.3%)、MMRd 63例(24%)、p53abn 62例(23.7%)、NSMP 118例(45%)。

临床怎么用

  • 对活检诊断的子宫内膜癌即可启动分子检测,以便在手术前获得分型并指导管理。
  • 分子结果可整合入最终切除标本的病理报告,标注TCGA分子类型。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Since the publication of The Cancer Genome Atlas (TCGA) molecular Classification of endometrial carcinomas in 2013, multiple studies have demonstrated the prognostic and therapeutic importance of this. However, there is great variability on whether and how this is undertaken in different institutions, and this is often dependent on resources and availability of molecular testing. Points of controversy include whether molecular classification is needed on all endometrial carcinomas and whether pure molecular testing is undertaken or a surrogate such as the ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) Classifier. Herein we report our experience instigating molecular classification of endometrial carcinomas in Northern Ireland. METHODS AND RESULTS: From 1st March 2023, all endometrial carcinomas diagnosed on biopsy in the four pathology laboratories in Northern Ireland were referred to the central molecular pathology laboratory for genomic analysis using a custom next-generation sequencing (NGS) panel; the NGS panel included the entire coding regions of polymerase epsilon (POLE) and TP53 genes, as well as microsatellite instability (MSI) analysis. All cases also underwent immunohistochemical staining with oestrogen receptor (ER), p53, and the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. The molecular results were available by the time of surgery (if a hysterectomy was performed) allowing integration into the final pathology report where a TCGA molecular type was assigned. Two hundred and sixty-seven endometrial carcinomas underwent molecular testing; in five cases, there was insufficient material for testing, leaving 262 cases. The TCGA groups were POLEmut (19; 7.3%), MMRd (63; 24%), p53abn (62; 23.7%), and no specific molecular profile (NSMP) 118 (45%). Seventeen tumours (6.5%) were "multiple-classifiers": five POLEmut-p53abn, two POLEmut-MMRd, one POLE-MMRd-p53abn (all included in the POLEmut TCGA group), and nine MMRd-p53abn (included in the MMRd group). CONCLUSION: This represents one of the first population-based studies investigating the prevalence of the different TCGA molecular groups of endometrial carcinomas in an unselected population. Performing molecular testing on biopsies enables management to be tailored to the molecular group and allows integration of the TCGA group into the report of the final resection specimen. We hope our experience will facilitate other laboratories in undertaking TCGA molecular classification.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Machuca-Aguado J, Catherwood M, Houghton O, et al. Initiation of molecular testing of endometrial carcinomas in a population-based setting: practical considerations and pitfalls. Histopathology. 2024. PMID: 39610022. doi:10.1111/his.15365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。